作者:Markus Hartmann、Jessica Huber、Jan S. Kramer、Jan Heering、Larissa Pietsch、Holger Stark、Dalibor Odadzic、Iris Bischoff、Robert Fürst、Martin Schröder、Masato Akutsu、Apirat Chaikuad、Volker Dötsch、Stefan Knapp、Ricardo M. Biondi、Vladimir V. Rogov、Ewgenij Proschak
DOI:10.1021/acs.jmedchem.0c01564
日期:2021.4.8
lysosomes. In this study, we show that the homologous members of the human Atg8 family proteins, LC3A and LC3B, are druggable by a small molecule inhibitor novobiocin. Structure–activity relationship (SAR) studies of the 4-hydroxy coumarin core scaffold were performed, supported by a crystal structure of the LC3A dihydronovobiocin complex. The study reports the first nonpeptide inhibitors for these protein
自噬是许多基于溶酶体的胞质货物降解途径的统称。自噬的关键成分是Atg8家族蛋白的成员,几乎参与了该过程的所有步骤,从自噬体形成到与溶酶体的选择性融合。在这项研究中,我们显示人类Atg8家族蛋白LC3A和LC3B的同源成员可通过小分子抑制剂新霉素进行药物治疗。在LC3A二氢新生物素复合物的晶体结构的支持下,进行了4-羟基香豆素核心支架的结构-活性关系(SAR)研究。